LC
NVO

Lavaca Capital’s Novo Nordisk NVO Stock Holding History

Lavaca Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9K Hold
840
– – 0.01% 196
2025
Q4 		$42.7K Hold
840
– – 0.01% 182
2025
Q3 		$46.6K Hold
840
– – 0.01% 170
2025
Q2 		$58K Hold
840
– – 0.02% 156
2025
Q1 		$58.3K Sell
840
-88
-9% -$7.27K 0.02% 146
2024
Q4 		$79.8K Buy
+928
New +$100K 0.03% 148
2019
Q2 		– Sell
-2,256
Closed -$59K – 257
2019
Q1 		$59K Hold
2,256
– – 0.05% 142
2018
Q4 		$52K Buy
+2,256
New +$50.1K 0.05% 127

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Lavaca Capital's NVO Position: Q1 2026 in Review

Lavaca Capital held its Novo Nordisk (NVO) position steady in Q1 2026 at 840 shares worth $30.9K. The position accounts for 0.01% of the portfolio, ranked #196.

Lavaca Capital first reported a position in NVO in Q4 2018 and has held it in 8 quarters since. The position peaked at $79.8K in Q4 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Lavaca Capital held 840 shares of Novo Nordisk worth $30.9K as of Q1 2026.
  • Lavaca Capital left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up 0.01% of Lavaca Capital's portfolio in Q1 2026, its #196 holding.
  • Lavaca Capital first reported a position in Novo Nordisk in Q4 2018 and has held it in 8 quarters since.
  • Lavaca Capital's Novo Nordisk position peaked at $79.8K in Q4 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Lavaca Capital's 13F filing for Q1 2026, filed 13 May 2026.